Duke University

Uti Limited Partnership

Clexio Biosciences Ltd.

Douglas Weitzel

Tuan Vo-Dinh

Paolo Maccarini

Morgan Carlson

Timothy A J Haystead

John Longan

Justin A MacDonald

Michael P Walsh

David A Carlson

Greg Palmer

Yang Liu

Brant A Inman

John P Majewski

Philip Chan

Ernest Erdosi

James Rudolph

Jr Alan D Kirkpatrick

The present disclosure is directed to compounds that may selectively inhibit Death Associated Protein Kinases (DAPKs) as well as PIM kinases. The compounds can be used in methods of treating various disorders, including cancers.

Kinase inhibitors and related methods of use

The presently disclosed subject matter is directed to a method of treating cancer, such as (but not limited to) metastatic bladder and breast cancer. The disclosed method comprises using two treatment modalities to synergistically treat primary and secondary tumor cells in a subject. The first element of the method comprises administering a therapeutically effective amount of a plasmonics-active metal nanoparticle to a subject comprising a primary cancer and a distant metastatic site, wherein the nanoparticle concentrates at the primary cancer. The method further comprises exposing the subject to photon radiation at the site of the primary cancer. The second element of the disclosed method comprises administering a therapeutically effective amount of an immune checkpoint modulator to the subject. The synergistic combination provides a rapid, safe, and effective treatment of local and distant lesions, better than each modality alone.

Synergistic nanotherapy systems and methods of use thereof

Growing community of inventors

Durham, NC, United States of America

Douglas Weitzel